Navigation Links
BiOptix announces expansion of Innovators Program at Molecular Med TRI-CON 2013
Date:2/12/2013

al Development & Production Week
  • US HUPO
  • AACR — The American Association for Cancer Research
  • 9th Annual Pegs — The Essential Protein Engineering Summit
  • 2013 Merck Technology Symposia
  • TIDES 2013 — Oligonucleotide and Peptide Research, Technology and Product Development
  • 2013 Bristol-Myers Squibb Vendor & Technology Symposia
  • Surface Plasmon Resonance is an advanced and highly sensitive optical technology that can measure refractive index changes on a sensor chip's gold surface due to a change in mass that occurs during a binding event. This change can be used to monitor biological interactions such as the concentration of target molecules, kinetic rates and affinity constants. BiOptix has developed and patented a novel ultra-sensitive detection platform known as Enhanced Surface Plasmon resonance, or ESPR. Unlike traditional SPR, ESPR instrumentation from BiOptix enables the high sensitivity of SPR with the high stability and lower noise of common path interferometry.

    About BiOptix

    BiOptix Diagnostics Corporation is a privately held firm based in Boulder, Colorado, with leading investments from Boulder Ventures and Rusnano.  BiOptix has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR – Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction—with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements. Additional information about BiOptix and our products can be found at:  

    SOURCE BiOptix Diagnostics Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. BiOptix Announces Fall 2012 Tradeshow and Symposia Schedule
    2. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
    3. OrbusNeich Announces Favorable Ruling From the European Patent Office
    4. Trovagene Announces Commercial Launch Timelines for HPV Carrier and Oncogene Mutation Tests
    5. Comprehensive Care Corporation Announces New Medicare Contract with Humana Health Plan of California, Inc.
    6. Unilife Corporation Announces Financial Results For Fiscal Year 2013 Second Quarter
    7. Regeneron Announces Receipt of Hart-Scott-Rodino Notice
    8. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
    9. Depomed Announces Appointment of Vicente J. Anido, Jr., Ph.D. to Board of Directors, and Retirement of Directors Julian N. Stern and Craig R. Smith, M.D.
    10. CPhI Announces its 2nd Annual Global Pharma Regulatory Summit
    11. Imprimis Pharmaceuticals Announces Pricing of Public Offering of 1,840,000 Shares of Common Stock
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2014)... IRIDEX Corporation (Nasdaq: IRIX ) today ... ended June 28, 2014.  , Revenues were $10.6 ... $9.2 million in the 2013 second quarter and up sequentially ... for the first six months of 2014 were $20.9 million, ... of last year. , Gross margin for the quarter ...
    (Date:7/31/2014)... Diabetes Care®, Inc. (NASDAQ: TNDM ), a medical ... reported its financial results for the quarter ended June 30, ... 2014 to the same period of 2013: , Sales ... , t:slim Pump shipments grew 64 percent to 2,235 pumps ... June 30, 2014 to the same period of 2013: ...
    (Date:7/31/2014)... Inc. (the "Company") (Nasdaq: PCYC ) today reported ... 30, 2014. Financial Results for the Six Months ... for the quarter ended June 30, 2014 increased to $113.0 ... 2013 primarily due to IMBRUVICA ® (ibrutinib) net product ... the six months ended June 30, 2014 increased to $232.4 ...
    Breaking Medicine Technology:IRIDEX Reports 2014 Second Quarter, Six-Month Results 2IRIDEX Reports 2014 Second Quarter, Six-Month Results 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 4IRIDEX Reports 2014 Second Quarter, Six-Month Results 5IRIDEX Reports 2014 Second Quarter, Six-Month Results 6IRIDEX Reports 2014 Second Quarter, Six-Month Results 7Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 3Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 4Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 5Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 6Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24Pharmacyclics Reports Second Quarter 2014 Results 25
    ... SAN FRANCISCO , June 22 Jennerex, Inc., ... Gregory W. Schafer as senior vice president and chief financial ... planning, investor relations and treasury functions. , ... "Greg,s finance and operations experience in the ...
    ... BENTONVILLE, Ark. , June 22 Walmart (NYSE: ... today they,re teaming up to provide an affordable insulin option for people with ... Beginning in mid-September, Lilly,s ... pharmacies across the U.S. under the dual-branded name Humulin ® ReliOn ...
    Cached Medicine Technology:Jennerex Appoints Gregory W. Schafer as Chief Financial Officer 2Jennerex Appoints Gregory W. Schafer as Chief Financial Officer 3Walmart, Lilly Team Up to Provide Human Insulin to People With Diabetes 2Walmart, Lilly Team Up to Provide Human Insulin to People With Diabetes 3Walmart, Lilly Team Up to Provide Human Insulin to People With Diabetes 4Walmart, Lilly Team Up to Provide Human Insulin to People With Diabetes 5
    (Date:8/1/2014)... Lake City, UT (PRWEB) August 01, 2014 ... Medical Billing Experts, LLC (MBX) with the convergence ... Medical Professionals (BOSS), Salt Lake City, UT; Premier ... Six Seven Group (67G) of Charlotte, NC. Together ... some of the nation’s largest radiology group practices, ...
    (Date:8/1/2014)... (PRWEB) August 01, 2014 According to the ... is a comprehensive diet guide for women who want to ... list of protein rich foods and fat loss ... muscle mass. , Vkool writes in its review that this ... the truth about fat burning hormones and weight loss supplements. ...
    (Date:8/1/2014)... The Journal of Neurosurgery is pleased ... the August issue entitled "Race Against the Clock: ... Hemorrhage." Authored by Peter Le Roux, MD, Charles ... and Alisa Schaefer, PhD, the 20-page supplement covers ... and methods in use for management of the ...
    (Date:8/1/2014)... Millions of women suffer with lipedema, a ... some cases the arms, causing an abnormal accumulation of ... women in the U.S. alone are affected. With such ... embarrassment and discomfort caused by lipedema, it’s remarkable that ... that this is a disease,” says Dr. David Greuner, surgical ...
    (Date:8/1/2014)... 2014 Register to join the webinar here: ... active years on record for life sciences investing. IPOs in ... 22 percent of all venture dollars spent in 2013. The ... valuations. , However, 2014 is proving more of a ... Silicon Valley Bank, while life sciences IPOs are losing steam, ...
    Breaking Medicine News(10 mins):Health News:Three Market Leaders Come Together As One To Form A New Breed of Medical Billing Companies 2Health News:Three Market Leaders Come Together As One To Form A New Breed of Medical Billing Companies 3Health News:The Metabolic Switch Diet PDF Review Exposes Sally Asher's Diet Guide For Boosting Metabolism – Vkool.com 2Health News:The Metabolic Switch Diet PDF Review Exposes Sally Asher's Diet Guide For Boosting Metabolism – Vkool.com 3Health News:Management of anticoagulant-associated intracerebral hemorrhage 2Health News:Management of anticoagulant-associated intracerebral hemorrhage 3Health News:Lipedema Centers Works With Insurers To Gain Coverage For Lipedema Treatment 2Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 2Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 3
    ... Dr. ... , and is giving patients in Texas new reasons to smile. , ... (Vocus) August 24, 2009 -- Mark Sweeney, DDS knows cosmetic dentistry… ... is director of Austin Dental Spa , a practice devoted to turning visits to the ...
    ... , SEATTLE, Aug. 24 Cell Therapeutics, Inc. ... and Drug Administration (FDA) has accepted and has filed for review ... relapsed or refractory aggressive non-Hodgkin,s lymphoma (NHL). A Prescription Drug User ... the review of the pixantrone NDA by September 4th 2009. ...
    ... Mortality remains high among patients with pulmonary arterial hypertension ... that were designed to reduce mortality and increase the ... out of University of California San Francisco. ... of the American Journal of Respiratory and Critical ...
    ... of Idiopathic Pulmonary Fibrosis is not much better than ... survival rate is less than three years. But ... targeting of a novel gene utilizing genetic and pharmacologic ... and will be developed for future testing in humans. ...
    ... ... Washington D.C. is business owner John Wahlquist of eMedicalSystems, Bremerton, Washington state. Author of his ... choice to retire his product and migrate his medical practices over to a new generation ... ...
    ... FAYETTE COUNTY, Ga. , Aug. 22 Dominique Wilkins, NBA ... create awareness of the fact that seniors at risk for diabetes ... provider,s office. This is the core message of the Medicare ... in Georgia since 2007 and is co-chaired nationally by the American ...
    Cached Medicine News:Health News:Austin Texas Cosmetic Dentist Celebrates 30 Years in Practice 2Health News:Austin Texas Cosmetic Dentist Celebrates 30 Years in Practice 3Health News:FDA Accepts to File Cell Therapeutics' New Drug Application for Pixantrone 2Health News:FDA Accepts to File Cell Therapeutics' New Drug Application for Pixantrone 3Health News:Still holding their breath: Mortality on lung transplant wait list remains high for some 2Health News:Still holding their breath: Mortality on lung transplant wait list remains high for some 3Health News:U-M researchers discover therapeutic target that could help patients with pulmonary fibrosis 2Health News:eMedical Systems, Inc. Selects MPMsoft as its Medical Billing Software Solution 2Health News:eMedical Systems, Inc. Selects MPMsoft as its Medical Billing Software Solution 3Health News:Dominique Wilkins Scores Big for Diabetes in Fayette County 2Health News:Dominique Wilkins Scores Big for Diabetes in Fayette County 3Health News:Dominique Wilkins Scores Big for Diabetes in Fayette County 4
    ... and Cronin, Inc. is ... Patient Footwear, Orthopedic Softgoods, ... Products. Our products are ... and available in the ...
    ... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
    SofTec Genu is the first functional brace that provides full soft tissue control, enhances natural muscle movement, prevents atrophy, increases proprioception and controls A/P laxity....
    ... hinged knee brace provides maximum ... types of sports and activities. ... rubber pads to support medial ... buttress and hyperextension stop. 3/16" ...
    Medicine Products: